CA-LAMBDATEST
2.2.2023 14:01:47 CET | Business Wire | Press release
LambdaTest, the leading continuous quality testing cloud platform, has announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005474/en/
LambdaTest’s digital experience testing cloud will enable enterprises to test for omnichannel experiences on custom-designed, robust, and scalable infrastructure (Graphic: Business Wire)
According to Forrester’s Best Practice Report titled ‘Optimize Your Digital Experience To Compete For Customers’, “No matter how embedded your brand is in customers’ lives today, if you stop meeting their expectations, it’s easy for them to switch to a competitor tomorrow. As the ratio of digital to nondigital customer interactions continues to increase, both digital customer experiences and the data that firms collect about them will evolve in ways that will challenge and reward insights-driven, customer-led organizations.”
Enterprises across the globe are striving to cater to the growing needs of digital-native customers. This translates to developers constantly working to provide a high-quality experience to customers while applications are undergoing continuous change. Such a high-pressure scenario demands quick developer feedback to enable faster release velocity. However, test execution ends up being the roadblock because enterprises depend on legacy cloud-based test execution platforms that are slow, brittle, and flaky or on in-house infrastructure that is hard to maintain, grow, and scale.
With LambdaTest’s digital experience testing cloud, enterprises can pick and choose across cross-browser testing (live and automated), real devices testing (live and automated), visual regression testing, and OTT app testing, thereby ensuring coverage across the entire gamut of omnichannel options. Moreover, the smart workflows like auto-grouping, auto-retry, and fail-fast techniques, offered by the testing cloud will do the heavy lifting, allowing testers/developers to concentrate on test creation.
Enterprises can decide their mode of deployment–multi-tenant, dedicated cloud, or on-premise. To top it off, enterprises will have access to centralized test analytics and observability that will unify all test execution data and enable informed decision-making.
The digital experience testing cloud will seamlessly fit into the CI/CD pipeline with 120+ integrations across categories like communication, bug tracking, test management, test authoring, and automation. Also, LambdaTest is SOC 2 Type II, ISO 27001, ISO 27017, and ISO 27701 standard certified, and GDPR, CCPA, and HIPAA-ready compliant.
“According to Gartner’s Market Guide for Digital Experience Monitoring, ‘By 2026, at least 60% of I&O leaders will use Digital Experience Monitoring to measure application, services and endpoint performance from the user’s viewpoint, up from less than 20% in 2021’. This clearly points to how central digital experience has become for enterprises. The LambdaTest digital experience testing cloud platform provides a comprehensive solution for modern enterprises to evolve their testing experience and thereby enhance the usability and performance of web and mobile applications to help deliver a best-in-class digital experience to their digital-native customers,” said Asad Khan, Co-Founder & CEO, LambdaTest.
“What we promise enterprises is straightforward and simple—our hyper-scalable digital experience testing cloud will be the digital highway for test execution and will reduce developer interrupts/friction, ensure faster feedback, and positively impact release velocity and go-to-market speed. This is bringing test execution to the digital era!” he added.
Recently, Satya Nadella, Chairman & CEO of Microsoft, delivered the keynote address at the Microsoft Future Ready Technology Summit 2023, Bengaluru, where he said that “LambdaTest is doing for test automation what Kubernetes did for container orchestration - creating that next level of efficiency around test automation so that people can actually focus on testing versus test orchestration.”
To know more, visit: https://www.lambdatest.com/enterprise
About LambdaTest
LambdaTest is a leading digital experience testing cloud that helps developers and testers ship code faster. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
The LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:
- Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.
- HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster.
For more information, please visit: https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005474/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom